This is an Individual Patient Expanded Access IND providing multiple administrations of
HBadMSCs for the treatment of Chronic Musculoskeletal Pain. The study duration is
approximately 32 weeks, during that time the study subject will complete 1 screening visit, 6
infusion visits, one follow-up visit without infusion and one end of study visit. Next day
telephone follow-up visits will occur following each infusion. Efficacy and safety labs as
well as quality of life and VAS scores will be obtained.